DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20202573

Device closure of patent ductus arteriosus: analysis of cases in a Bangladeshi centre

Nurun N. Fatema, Abul K. M. Razzaque

Abstract


Background: Transcatheter closure of Patent ductus arteriosus (PDA) has become the first-choice therapy for closure in patients of any age group. Authors reviewed the outcome of device closure in all age groups starting from neonate to adult.

Methods: From December 2014 to December 2019, 440 cases underwent transcatheter closure in a catheterization laboratory of a tertiary level cardiac hospital. Selection criteria were isolated PDA or PDA with associated conditions which can be managed in the same setting by an intervention. Exclusion criteria were proven Eisenmenger syndrome. A retrospective review of outcome and complications were recorded from computerized data records.

Results: Age of the patient varied from 10 days to 65 years. The median age was 3 years. Most of the patients were female (63%), weight varied from 1.8 kg to 75 kg. the median weight was 7.5 kg. Isolated PDA cases were 74.77 %. Among syndromes, congenital rubella syndrome was common (7.5%), followed by Down Syndrome (6.36%). The narrowest PDA diameter varied for 1.8 mm - 14 mm with a median of 5 mm. Among duct occluders, 8x6 mm CeraTM was the commonest one used in the study population. Complete occlusion was observed in 99.55% of cases.

Conclusions: Transcatheter closure of PDA is considered safe and efficacious in all age groups. It is the gold standard now and replaced surgical option in most of the places.


Keywords


Complications, Outcome, Patent ductus arteriosus

Full Text:

PDF

References


Fatema NN. Pattern of Congenital Heart Diseases and Treatment Options in a Bangladeshi Centre: Analysis of 6914 cases from Non-invasive Cardiac Laboratory. Cardiovasc J. 2017;9(2):97-105.

Ali S, El Sisi A. Transcatheter closure of patent ductus arteriosus in children weighing 10 kg or less: Initial experience at Sohag University Hospital. J Saudi Heart Assoc. 2016 Apr 1;28(2):95-100.

Sudhakar P, George OK. Contemporary outcome of percutaneous closure of patent ductus arteriosus in adolescents and adults. Indian Heart J. 2018; 70(2):308-15.

Fatema NN. Device Closure of Patent Ductus Arteriosus in Patient with Congenital Rubella Syndrome and Severe Pulmonary Hypertension: Report of Two Cases. JAFMC Bangladesh. 2011;7(1):43-5.

Kim Y, Choi JY, Lee JK, Sul JH, Lee SK, Park YH, et al. Mid-term result of the transcatheter occlusion of patent ductus arteriosus with Duct-Occluder device and procedure-related problems. Korean J Pediatr. 2004;47(1):36-43.

Porstmann W, Wierny L, Warnke H. Closure of persistent ductus arteriosus without thoracotomy. Ger Med Mon. 1967;12(6):259‐61.

Pass RH, Hijazi Z, Hsu DT, Lewis V, Hellenbrand WE. Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J Am Coll Cardiol. 2004;44(3):513‐9.

Lee LK , Woodfin MY, Vadi MG, Grogan T, Ross PR, Applegate RL, et al. comparison of postoperative outcomes with PDA ligation in the OR versus the NICU: a retrospective cohort study on the risks of transport. BMC Anesthesiol. 2018;18(1):199.

Wang K, Pan X, Tang Q, Pang Y. Catheterization therapy vs surgical closure in pediatric patients with patent ductus arteriosus: a meta-analysis. Clin Cardiol. 2014;37(3):188‐94.

Sommer RJ, Gutierrez A, Lai WW, Parness IA. Use of preformed nitinol snare to improve transcatheter coil delivery in occlusion of patent ductus arteriosus. Am J Cardiol. 1994;74(8):836‐9.

Podnar T, Gavora P, Masura J. Percutaneous closure of patent ductus arteriosus: complementary use of detachable Cook patent ductus arteriosus coils and Amplatzer duct occluders. Eur J Pediatr. 2000;159(4):293‐6.

Saliba Z, Aggoun Y, Hausse AO, Acar P, Bonnet D, Fraisse A, et al. Percutaneous closure of patent ductus arteriosus with the Amplatzer duct occlude. Archives des Maladies du Coeur et des Vaisseaux. 2000 May;93(5):533-8.

Marwah A, Radhakrishnan S, Shrivastava S. Immediate and early results of closure of moderate to large patent arterial ducts using the new Amplatzer device. Cardiol Young. 2000;10(3):208‐11.

Thanopoulos BV, Hakim FA, Hiari A, Goussous Y, Basta E, Zarayelyan AA, et al. Further experience with transcatheter closure of the patent ductus arteriosus using the Amplatzer duct occluder. J Am Coll Cardiol. 2000 Mar 15;35(4):1016-21.

Behjati-Ardakani M, Behjati-Ardakani MA, Hosseini SH, Noori N. Long-term results of transcatheter closure of patent ductus arteriosus in infants using amplatzer duct occluder. Iran J Pediatr. 2013;23(4):411‐6.

Ullah M, Sultan M, Akhtar K, Sadiq N, Akbar H. Percutaneous transcatheter PDA device closure in infancy. J Coll Physicians Surg Pak. 2014;24(8):581‐5.

Krichenko MD, Benson LN, Burrows P, Möes CA, McLaughlin P, Freedom RM. Angiographic classification of the isolated persistently patent ductusarteriosus and implications for percutaneous catheter occlusion. Am J Cardiol. 1989;63(12):877-80.

Park YA, Kim NK, Park SJ, Yun BS, Choi JY, Sul JH. Clinical outcome of transcatheter closure of patent ductusarteriosus in small children weighing 10 kg or less. Korean J Pediatr. 2010;53:1012-7.

Backes CH, Cheatham SL, Deyo GM, Leopold S, Ball MK, Smith CV, et al. Percutaneous Patent Ductus Arteriosus (PDA) Closure in Very Preterm Infants: Feasibility and Complications. J Am Heart Assoc. 2016;5(2):e002923.

Kumar SM, Subramanian V, Bijulal S, Krishnamoorthy KM, Sivasankaran S, Tharakan JA. Percutaneous closure of a moderate to large tubular or elongated patent ductus arteriosus in children younger than 3 years: is the ADO II appropriate?. Pediatr Cardiol. 2013;34(7):1661‐7.

Butera G, De Rosa G, Chessa M, Piazza L, Delogu A, Frigiola A, et al. Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart. 2004;90(12):1467-70.

Sathanandam S, Gutfinger D, O'Brien L et al. Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥700 grams. Catheterization and Cardiovascular Interventions. 2020.

Sathanandam S. Transcatheter PDA closure using the Amplatzer Piccolo occluder device in premature infants less than 2 kg. Real world Registry study. 2018.

Masura J, Tittel P, Gavora P, Podnar T. Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders. Am Heart J. 2006;151(3):755.

Jang GY, Son CS, Lee JW, Lee JY, Kim SJ. Complications after transcatheter closure of patent ductus arteriosus. J Korean Med Sci. 2007;22(3):484‐90.

Dimas VV, Takao C, Ing FF, Mattamal R, Nugent AW, Grifka RG, et al. Outcomes of transcatheter occlusion of patent ductus arteriosus in infants weighing ≤6 kg. JACC Cardiovasc Interv. 2010;3(12):1295‐9.

Wang JK, Wu MH, Hwang JJ, Chiang FT, Lin MT, Lue HC. Transcatheter closure of moderate to large patent ductus arteriosus with the Amplatzer duct occluder. Catheter Cardiovasc Interv. 2007;69(4):572‐8.

Al-Ata J, Arfi AM, Hussain A, Kouatli AA, Jalal MO. The efficacy and safety of the Amplatzer ductal occluder in young children and infants. Cardiol Young. 2005;15(3):279‐85.

Lee CH, Leung YL, Chow WH. Transcatheter closure of the patent ductus arteriosus using an Amplatzer duct occluder in adults. Jpn Heart J. 2001;42(4):533‐7.

El-Said HG, Bratincsak A, Foerster SR, Murphy JJ, Vincent J, Holzer R et al. Safety of percutaneous patent ductus arteriosus closure: an unselected multicenter population experience. J Am Heart Assoc. 2013;2(6):e000424.